Albumin-interferon alpha2b fusion protein - Tianjin SinoBiotech

Drug Profile

Albumin-interferon alpha2b fusion protein - Tianjin SinoBiotech

Latest Information Update: 19 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Tianjin SinoBiotech
  • Class Albumins; Antineoplastics; Antivirals; Interferons; Recombinant fusion proteins
  • Mechanism of Action Interferon alpha 2b stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hepatitis C

Most Recent Events

  • 12 Apr 2017 Tianjin SinoBiotech completes a phase I trial in Hepatitis C (In volunteers) in China (NCT02781753)
  • 07 Apr 2016 Phase-I clinical trials in Hepatitis C (In volunteers) in China (SC) (NCT02781753)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top